About
Technology
Issues
FAQ
Links
Official Page
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.